Jin Medical International Ltd. is a Cayman Islands holding company operating in China that designs, develops, manufactures, and markets wheelchairs and other living aids for people with disabilities, the elderly, and individuals recovering from injury. Founded in 2006 and headquartered in Changzhou, Jiangsu Province, the company produces manual and electric wheelchairs, wheelchair components, oxygen concentrators, bath aids, walking aids, micro-hyperbaric oxygen chambers, and other rehabilitation products.
Jin Medical operates manufacturing bases in Changzhou, Taizhou, and Chuzhou, holds more than 200 patents, and is certified to the ISO 13485 quality standard. Its products are sold through a network of distributors in China, Japan, and other international markets, and its customers include hospitals and rehabilitation providers. The company listed on Nasdaq in March 2023 and remains a small-cap name with a highly concentrated revenue base; one customer, Nissin, has accounted for a substantial share of revenue in recent periods. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the trailing 30 days, ZJYL advanced approximately 74%, moving from a closing level near $1.91 in mid-October to about $3.33 in the most recent session. The move was not linear: the stock consolidated near $1.86 to $1.91 in late October before surging on sharply higher volume, climbing through $4.90 intraday in early-to-mid November and then pulling back into the low-to-mid $3 range.
The last quarter tells a broader story of extreme volatility. From a closing level around $3.03 in mid-August, the shares are up roughly 10% over the three-month window, but the path included an August spike toward $3.74 intraday, a steady September-to-October decline toward the mid-$1.80s, and a powerful November recovery. This whipsaw pattern reflects a low-float stock where relatively small trading volumes can drive outsized price swings.
The dominant catalyst behind the recent advance was the completion of the company's $159.4 million acquisition of Huaxia Qiying, closed on September 24, 2026. The deal was settled primarily through the issuance of roughly 71.3 million Class A ordinary shares plus advisory shares, marking a transformative step for a company whose market capitalization had been far smaller. Investor attention on this transaction, combined with subsequent corporate updates, provided the fundamental backdrop for the re-rating.
Momentum and thin liquidity amplified the move. Trading volume spiked to well over a million shares on several sessions in late October and November, versus a much lower historical average, and the stock experienced multiple LULD volatility pauses. Community and brand announcements added fuel: on November 3, Jin Medical announced it was supplying wheelchairs and accessibility services for the 12th Jiangsu Provincial Games for Persons with Disabilities, an event the company tied to its twentieth anniversary in the rehabilitation assistive device industry.
The broader quarterly trend reflects a company in transition rather than a steady uptrend. In August, the shares spiked following the reporting of first-half fiscal 2026 results and the unfolding Huaxia Qiying acquisition narrative, before giving back those gains as dilution from the share issuance and a still-weak earnings picture weighed on sentiment.
The company's fundamentals were soft entering the quarter: for the six months ended March 31, 2026, Jin Medical reported revenue of roughly $8.9 million, down 9.7% year over year, and a small net loss. A 1-for-20 share combination completed in March 2026 had already reshaped the capital structure as part of a Nasdaq compliance effort, and the company regained compliance with the exchange's minimum bid price requirement in April 2026. The November rally therefore represents a re-rating off a depressed base, driven primarily by the transformative acquisition rather than an improvement in operating results. From what I see, this context helps frame why the move has been so sharp.
Investors monitoring ZJYL should watch for integration updates tied to the Huaxia Qiying acquisition, including how the new business contributes to revenue and whether the significant share issuance weighs on per-share metrics. Upcoming earnings reports will be critical for confirming whether the company can reverse the recent revenue decline and return to profitability.
Other factors to monitor include the company's high customer concentration, particularly its dependence on a single major distributor, ongoing expansion of the Chuzhou manufacturing facility, and any further capital-raising or compliance developments. Given the stock's low float, elevated beta, and history of volatility pauses, price action may remain prone to sharp moves on limited news. As with any small-cap security, investors should weigh these risks carefully and rely on verified financial disclosures. I’m watching this closely as the integration unfolds.
In my research process, I often turn to Tickeron’s AI Trading Bots to test how automated strategies might align with names like this one amid volatile moves. The platform offers a range of bots with different timeframes and approaches, which helps me compare signals across the market without relying solely on manual charting. It’s become a practical part of how I review potential setups in low-float names.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The Stochastic Oscillator for ZJYL moved into oversold territory on November 19, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on ZJYL as a result. In 70 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
ZJYL moved above its 50-day moving average on October 30, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ZJYL crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 9 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 89%.
Following a +0.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZJYL advanced for three days, in 162 of 188 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The 10-day RSI Indicator for ZJYL moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In 21 of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for ZJYL turned negative on November 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 29 similar instances when the indicator turned negative. In 28 of the 29 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZJYL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ZJYL broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. ZJYL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 84 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.351) is normal, around the industry mean (4.964). ZJYL's P/E Ratio (336.000) is considerably higher than the industry average of (40.591). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.750) is also within normal values, averaging (56.876).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZJYL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry PharmaceuticalsOther